Table 1. Summary of drugs screened in senescent AEC model, their respective IC₅₀s per endpoint, and their fold selectivity for senescent versus non-senescent AECs.

Drug	Mechanism	Class	IC50 (μM)						Senescence Selectivity (fold)
			CellTiter-Glo		IL-6		IL-8
			Non-senescent AECs	Senescent AECs	Non-senescent AECs	Senescent AECs	Non-senescent AECs	Senescent AECs	CellTiter-Glo	IL-6	IL-8
Nintedanib	TGF-β signaling	Anti-fibrotic (SoC)	48.1 ± 3.0	24.1 ± 19.2	50	38.2 ± 14.3	34.2 ± 16.9	37.9 ± 14.4	2.0	1.3	0.9
ABT-317	Jak1	Senomorphic	10	10	10	10	10	10	1.0	1.0	1.0
Ruxolitinib	Jak1/2	Senomorphic	10	10	10	10	10	10	1.0	1.0	1.0
Navitoclax	Bcl-2/xL	Senolytic	2.6 ± 3.8	0.06 ± 0.03	9.4 ± 0.55	0.13 ± 0.03	10	0.07 ± 0.02	44.6	71.0	134.2
AD80	RET, Raf, SRC, S6K	Senomorphic and weak senolytic	2.3 ± 0.5	0.46 ± 0.75	0.5 ± 0.1	0.42 ± 0.13	0.73 ± 0.13	0.37 ± 0.03	5.1	1.2	1.9

Values represent the geometric mean ± SEM of 3-4 experimental repeats.